Enterprise Value

779.2M

Cash

207.4M

Avg Qtr Burn

-24.79M

Short % of Float

13.16%

Insider Ownership

0.18%

Institutional Own.

95.76%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details
Essential tremor

Big Mover™

Susp. Mover™

Phase 3

Data readout

PRAX-628 Details
Epilepsy, Focal Onset Seizures

Phase 2b

Initiation

Phase 2

Data readout

PRAX-562 Details
Developmental and Epileptic Encephalopathy

Phase 2

Data readout

PRAX-222 Details
Developmental and Epileptic Encephalopathy

Phase 1/2

Data readout

Failed

Discontinued

Failed

Discontinued